Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 3-ib-meca
2. N(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine
3. N(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide
4. N(6)-ibamu
1. Piclidenoson
2. 152918-18-8
3. Cf-101
4. 3-ib-meca
5. Cf 101
6. N(6)-ibamu
7. Cf101
8. N(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine
9. Piclidenoson [usan]
10. 1-deoxy-1-(6-(((3-iodophenyl)methyl)amino)-9h-purin-9-yl)-n-methyl-beta-d-ribofuranuronamide
11. Chembl119709
12. (2s,3s,4r,5r)-3,4-dihydroxy-5-[6-[(3-iodophenyl)methylamino]purin-9-yl]-n-methyloxolane-2-carboxamide
13. Chebi:73286
14. 30679umi0n
15. (2s,3s,4r,5r)-3,4-dihydroxy-5-(6-((3-iodobenzyl)amino)-9h-purin-9-yl)-n-methyltetrahydrofuran-2-carboxamide
16. 3-iodobenzyl-5'-n-methylcarboxamidoadenosine
17. N6-(3-iodobenzyl)adenosine-5'-n-methyluronamide
18. (2s,3s,4r,5r)-3,4-dihydroxy-5-(6-(3-iodobenzylamino)-9h-purin-9-yl)-n-methyltetrahydrofuran-2-carboxamide
19. N(6)-(3-iodo-benzyl)adenosine-5'-n-methyluronamide
20. (2s,3s,4r,5r)-5-{6-[(3-iodobenzyl)amino]-9h-purin-9-yl}-3,4-dihydroxy-n-methyltetrahydrofuran-2-carboxamide
21. N(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide
22. Unii-30679umi0n
23. Rpr-113090
24. 1-deoxy-1-[6-[[(3-iodophenyl)methyl]amino]-9h-purin-9-yl]-n-methyl-beta-d-ribofuranuronamide
25. Ibmeca
26. Piclidenoson (usan/inn)
27. Piclidenoson [inn]
28. Gtpl422
29. Mls002153391
30. Piclidenoson [who-dd]
31. Schembl465039
32. Regid_for_cid_123683
33. Dtxsid50165158
34. Hms2234i04
35. Hms3412e09
36. Hms3676e09
37. 3,4-dihydroxy-5-[6-(3-iodo-benzylamino)-purin-9-yl]-tetrahydro-furan-2-carboxylic Acid Methylamide
38. Cf-101; Ib-meca; Piclidenoson
39. Ex-a2514
40. Zinc3811810
41. Bdbm50118812
42. Mfcd00671785
43. Si-615
44. Akos024456363
45. Cs-5048
46. Db05511
47. Ib-meca, Solid, >=98% (hplc)
48. Ncgc00024978-02
49. Ncgc00024978-03
50. Ncgc00024978-04
51. Ncgc00024978-05
52. Ncgc00024978-09
53. Ac-36111
54. As-16876
55. Beta-d-ribofuranuronamide, 1-deoxy-1-(6-(((3-iodophenyl)methyl)amo)-9h-purin-9-yl)-n-methyl-
56. Hy-13591
57. Smr001230772
58. D10971
59. A848868
60. J-008958
61. N6-(3-iodobenzyl)-5''-n-methylcarboxamidoadenosine
62. (n-6-(3-iodobenzyl)adenosine-5''-n-methyluronamide
63. Q27088384
64. Adenosine, N(6)-[3-iodobenzyl]-4'-methylcarbamoyl-4'-dehydroxymethyl-
65. 1-deoxy-1-[6-[[(3-iodophenyl)methyl]amino]-9h-purin-9-yl]-n-methyl-?-d-ribofuranuronamide
66. (2r,3r,4s,5s)-5-(6-(3-iodobenzylamino)-9h-purin-9-yl)-3,4-dihydroxy-n-methyl-tetrahydrofuran-2-carboxamide;cf 101
67. (2s,3s,4r,5r)-3,4-dihydroxy-5-[6-(3-iodo-benzylamino)-purin-9-yl]-tetrahydro-furan-2-carboxylic Acid Methylamide
68. (2s,3s,4r,5r)-5-(6-(3-iodobenzylamino)-9h-purin-9-yl)-3,4-dihydroxy-n-methyl-tetrahydrofuran-2-carboxamide
69. (3r,4s,5r)-3,4-dihydroxy-5-[6-(3-iodo-benzylamino)-purin-9-yl]-tetrahydro-furan-2-carboxylic Acid Methylamide
70. (3s,4r,5r)-3,4-dihydroxy-5-[6-(3-iodo-benzylamino)-purin-9-yl]-tetrahydro-furan-2-carboxylic Acid Methylamide
71. .beta.-d-ribofuranuronamide, 1-deoxy-1-(6-(((3-iodophenyl)methyl)amino)-9h-purin-9-yl)-n-methyl-
72. 1-deoxy-1-[6-[[(3-iodophenyl)methyl]amino]-9h-purin-9-yl]-n-methyl-beta-d-ribofuranuronamide;n6-(3-iodobenzyl)adenosine-5'-n-methyluronamide;(2r,3r,4s,5s)-5-(6-(3-iodobenzylamino)-9h-purin-9-yl)-3,4-dihydroxy-n-methyl-tetrahydrofuran-2-carboxamide;cf 101
| Molecular Weight | 510.3 g/mol |
|---|---|
| Molecular Formula | C18H19IN6O4 |
| XLogP3 | 0.9 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 5 |
| Exact Mass | 510.05125 g/mol |
| Monoisotopic Mass | 510.05125 g/mol |
| Topological Polar Surface Area | 134 Ų |
| Heavy Atom Count | 29 |
| Formal Charge | 0 |
| Complexity | 589 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 4 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in cancer/tumors (unspecified), eye disorders/infections, psoriasis and psoriatic disorders, and rheumatoid arthritis. Can-Fite BioPharma has reported that by targeting the adenosine A3-receptor, CF101 may also be used to treat Crohn's disease, a serious gastrointestinal disorder.
CF-101 is an adenoside A3 agonist for the treatment of a variety of autoimmune-inflammatory disorders, particularly rhematoid arthritis. In clinical trials, it was found to be safe, well tolerated and showed strong evidence of an anti-inflammatory effect in rheumatoid arthritis patients. In this trial, a statistically significant correlation was found between A(3)AR expression level and response to the drug, so A(3)AR expression may serve as a biopredictor of patient response.
CF 101 is an A(3)AR agonist. A(3)AR is highly expressed in inflammatory cells and overexpressed in peripheral blood mononuclear cells, reflecting its role in the remote inflammatory process. In normal tissues, there is low adenoside A3 receptor expression. A(3)AR activation with a specific agonist deregulates the NF-kappaB signaling pathway in inflammatory cells and initiates immunomodulatory effects.
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
47
PharmaCompass offers a list of Piclidenoson API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Piclidenoson manufacturer or Piclidenoson supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Piclidenoson manufacturer or Piclidenoson supplier.
PharmaCompass also assists you with knowing the Piclidenoson API Price utilized in the formulation of products. Piclidenoson API Price is not always fixed or binding as the Piclidenoson Price is obtained through a variety of data sources. The Piclidenoson Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Piclidenoson manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Piclidenoson, including repackagers and relabelers. The FDA regulates Piclidenoson manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Piclidenoson API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Piclidenoson supplier is an individual or a company that provides Piclidenoson active pharmaceutical ingredient (API) or Piclidenoson finished formulations upon request. The Piclidenoson suppliers may include Piclidenoson API manufacturers, exporters, distributors and traders.
Piclidenoson Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Piclidenoson GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Piclidenoson GMP manufacturer or Piclidenoson GMP API supplier for your needs.
A Piclidenoson CoA (Certificate of Analysis) is a formal document that attests to Piclidenoson's compliance with Piclidenoson specifications and serves as a tool for batch-level quality control.
Piclidenoson CoA mostly includes findings from lab analyses of a specific batch. For each Piclidenoson CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Piclidenoson may be tested according to a variety of international standards, such as European Pharmacopoeia (Piclidenoson EP), Piclidenoson JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Piclidenoson USP).
